Halozyme Therapeutics (NASDAQ:HALO) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reiterated their buy rating on shares of Halozyme Therapeutics (NASDAQ:HALO) in a report released on Wednesday morning, Benzinga reports. The brokerage currently has a $50.00 price objective on the biopharmaceutical company’s stock.

Other equities research analysts also recently issued reports about the company. JMP Securities decreased their price target on Halozyme Therapeutics from $72.00 to $71.00 and set a market outperform rating for the company in a report on Wednesday, May 8th. StockNews.com raised Halozyme Therapeutics from a hold rating to a buy rating in a report on Friday, February 23rd. TD Cowen initiated coverage on Halozyme Therapeutics in a report on Thursday, February 29th. They set an outperform rating and a $54.00 price target for the company. Finally, Benchmark reaffirmed a buy rating and set a $50.00 price target on shares of Halozyme Therapeutics in a report on Tuesday, April 16th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and an average target price of $53.14.

Halozyme Therapeutics Price Performance

HALO stock opened at $43.82 on Wednesday. The company has a market capitalization of $5.58 billion, a P/E ratio of 18.11, a PEG ratio of 0.49 and a beta of 1.26. Halozyme Therapeutics has a twelve month low of $31.86 and a twelve month high of $46.16. The business has a 50 day simple moving average of $40.88 and a 200-day simple moving average of $38.84. The company has a current ratio of 6.64, a quick ratio of 5.36 and a debt-to-equity ratio of 8.44.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing the consensus estimate of $0.77 by ($0.02). Halozyme Therapeutics had a return on equity of 225.71% and a net margin of 36.94%. The company had revenue of $230.04 million for the quarter, compared to analyst estimates of $235.25 million. As a group, equities analysts anticipate that Halozyme Therapeutics will post 3.44 EPS for the current year.

Insiders Place Their Bets

In other news, SVP Michael J. Labarre sold 10,000 shares of the firm’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $41.64, for a total value of $416,400.00. Following the completion of the transaction, the senior vice president now owns 156,558 shares in the company, valued at $6,519,075.12. The sale was disclosed in a document filed with the SEC, which is available at this link. Over the last quarter, insiders sold 40,000 shares of company stock worth $1,650,600. 2.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Rise Advisors LLC purchased a new position in shares of Halozyme Therapeutics in the first quarter valued at $25,000. Whittier Trust Co. purchased a new position in shares of Halozyme Therapeutics in the first quarter valued at $27,000. Principal Securities Inc. purchased a new stake in Halozyme Therapeutics during the 4th quarter worth about $34,000. Fidelis Capital Partners LLC purchased a new stake in Halozyme Therapeutics during the 1st quarter worth about $52,000. Finally, First Horizon Advisors Inc. increased its position in Halozyme Therapeutics by 24.5% during the 4th quarter. First Horizon Advisors Inc. now owns 1,491 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 293 shares in the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.